AMEX · ELMD

Electromed, Inc.

$39.86 +$1.45 (+3.78%) 1D After hours

Key Metrics

$318.04M
Market cap
31.48×
P/E · TTM
$71.75M
Revenue · TTM
$10.10M
Net income
EPS · TTM $1.16
Dividend yield
Free cash flow $9.35M
Beta · 1Y 0.87
EBITDA · TTM $14.59M
Gross margin 78.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 13
    The stock moved +25.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 13
  • Feb 11
    The stock moved -10.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$318.04M
Enterprise value
Shares outstanding8.3M
52-wk range$17.73 – $47.40
Avg volume · 20D43.0K
Net cash
Book value / share$5.67
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeAMEX
About Electromed, Inc.
IPO dateAug 13, 2010
Employees180

Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and co…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E31.48
P/S4.43
P/FCF34.01
EV/EBITDA
EV/Sales
Graham №$12.19

Profitability

Gross 78.4%
Operating 18.9%
Net 14.1%
FCF 13.0%
ROE / ROIC 21.6% · 31.4%

Financial Health

Current ratio4.91
Quick ratio4.59
Debt / equity
Debt / EBITDA
Net cash
Working capital$40.00M

Cash Flow · TTM

Operating CF $10.53M
Capex −$1.18M
Free cash flow $9.35M
Buybacks $7.59M
Dividends paid
Shareholder yield 2.4%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

21.9
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$12.19 vs $39.86
Trades 3.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings